As demand for convenient GLP-1 access continues growing in 2026, this Maximus GLP-1 review explores how its clinician-reviewed, direct-pay telehealth program is positioned to support eligible adults pursuing weight-management goals, while comparing compounded and FDA-approved options, current pricing, pharmacy fulfillment, customer complaints, and the critical details buyers should verify before enrolling.
SANTA MONICA, CA / ACCESS Newswire / July 31, 2026 / Quick note on the title: "Reviews & Complaints" means brand-published testimonials, real BBB complaints, and this article's own review - not a star rating this publication assigns. "The FDA Warning Letter" refers to an actual FDA letter and specific, still-live language on Maximus's own homepage, both detailed below with a direct link to FDA.gov. This publication doesn't independently vouch for any brand claim below - the specifics are coming up.
Quick disclosure, too: this is a paid advertorial, and it's promotional content meant to help you understand a commercially available product. A commission is earned if you buy through links here - some route through an affiliate partner before reaching Maximus's own site. Everything below is attributed to Maximus, not independently endorsed by this publication. Maximus GLP-1 includes compounded medications that haven't received FDA clearance or approval; this isn't medical advice, and any prescription requires a licensed provider's evaluation and approval, which isn't guaranteed. Medical emergency? Call 911. Official site: maximustribe.com/weight-loss. Info here reflects July 2026 - confirm anything that matters to you directly with Maximus before ordering.
Check your Maximus GLP-1 price and eligibility
Maximus GLP-1 Reviews and Complaints: Researching The FDA Warning Letter, Conflicting Prices, and What Buyers May Discover Before Enrolling (Consumer Research)
So you saw the ad - maybe a GLP-1 post on Instagram, maybe a friend's story, maybe a testosterone spot squeezed in before your video finally loaded. Now you're here doing exactly what a smart shopper does before entering a card number: checking the details. Good instinct. Three entities sit behind every Maximus GLP-1 prescription you'd actually receive - Maximus Health, Inc. (the platform), the Maximus Medical Group Practices (the doctors who decide), and a pharmacy partner (who fills it) - and this article walks through exactly what to verify with each before you enroll.
Maximus GLP-1 is a telehealth weight-loss program run through three entities: Maximus Health, Inc. (the platform), the Maximus Medical Group Practices (the prescribing physicians), and a pharmacy fulfillment partner. Maximus publishes different first-month and ongoing prices by medication and dose: compounded semaglutide from $149.99 the first month ($249.99/month after), compounded tirzepatide from $259.99 the first month ($359.99/month after), plus FDA-approved options including Ozempic, Wegovy, Mounjaro, and Zepbound. The medical group reviews every applicant before any prescription is written. It's built for adults wanting clinician-reviewed, insurance-free weight-loss care, HSA/FSA-eligible, available in most states.
Here's everything that ad left out - starting with who's actually behind the prescription, and ending with an FDA letter Maximus would probably rather you not read.
What Is Maximus GLP-1 and Who Is It For?
If you're carrying extra weight and have looked at GLP-1 medications like Ozempic or Wegovy but balked at the price tag or the idea of navigating insurance pre-authorization, Maximus is built for that exact frustration. According to the brand, Maximus is a performance-medicine telehealth company founded in 2020 that covers testosterone optimization, GLP-1 weight loss, blood flow, mood and stress, hair regrowth, and growth hormone peptides - all under one clinical team, direct-pay, no insurance required.
The GLP-1 side of the business offers two paths: compounded tirzepatide or semaglutide prepared by a pharmacy partner at a lower price point, or FDA-approved brand-name injections and tablets (Ozempic, Wegovy, Zepbound, Mounjaro, Foundayo) at a higher price point. Both paths, according to the brand, are clinician-reviewed, and clients can switch between compounded and brand-name as their needs change.
Buyer takeaway: if what's stopping you from starting a GLP-1 protocol is the process of getting a prescription - not the medication itself - this is the kind of platform built around that specific friction point. Whether the specific pricing, refund terms, and entity structure fit your situation is what the rest of this article helps you verify.
For a closer look at the base pricing structure and step-by-step protocol details before the FDA warning letter below became public, see prior coverage of Maximus's GLP-1 pricing, protocols, and compounding facts. This article picks up where that one left off, focusing on what's changed since and what still needs independent verification.
The Three Entities Behind Every Maximus Prescription
Before you enter any payment information, it helps to understand who is actually doing what. Per the official website and the brand's own Telehealth Informed Consent document, three separate entities are involved in every Maximus GLP-1 order:
Maximus Health, Inc. (the platform). This is the company behind the website, the app, customer support, intake forms, billing, and shipping coordination. According to the company's own Terms of Use, Maximus Health, Inc. does not provide medical advice, medical services, or medical care, and does not itself prescribe medication.
Maximus Medical Group Practices (the providers, referred to in the brand's own consent documents as "Group"). These are the affiliated, independently licensed medical practices whose physicians review each applicant's intake information, order labs when appropriate, and make the actual prescribing decision. The brand's own Telehealth Informed Consent states plainly that "Maximus Health, Inc. does not provide the Services; it performs administrative, payment, and other supportive activities for Group and our Providers." A prescription is never guaranteed.
A pharmacy fulfillment partner. Per the brand's help center, name-brand GLP-1 medications are currently dispensed through The Pharmacy Hub (TPH), a national pharmacy-fulfillment company that serves multiple telehealth platforms. Compounded medications are fulfilled through one of three licensed 503A compounding pharmacies - EVR, FCC, or VIOS - depending on the patient's state, per the same help-center article. Ask which of these will fill your specific order and confirm its state licensure before you commit to a plan.
Buyer takeaway: medical questions go to the medical group, billing questions go to Maximus Health, Inc., and medication-quality questions ultimately trace back to the dispensing pharmacy - The Pharmacy Hub for name-brand orders, or EVR, FCC, or VIOS (depending on your state) for compounded orders. Knowing which entity owns which part of the relationship makes it easier to get a straight answer if something goes wrong later.
Compounded vs. FDA-Approved: What Maximus Actually Offers
According to the brand, the GLP-1 lineup breaks into two clearly separated tracks. Maximus currently publishes different introductory and ongoing prices depending on the medication, dose, and plan structure - confirm the exact current amount at checkout, since promotional and prepaid-plan pricing can differ from the figures below.
Compounded Tirzepatide - a dual GIP/GLP-1 receptor agonist; the brand states this activates two hormone receptor pathways rather than one. Per the brand's help center, pricing starts at $259.99 for the first month and $359.99 per month ongoing, with lower per-month rates available on 4, 6, and 12-month prepay plans.
Compounded Semaglutide - a single-mechanism GLP-1 receptor agonist, described by the brand as "the medicine that started the weight loss GLP-1 revolution." Per the brand's help center, pricing starts at $149.99 for the first month and $249.99 per month ongoing, with lower prepay rates also available.
Foundayo™ Tablets (orforglipron) - FDA-approved oral GLP-1 medication; according to the brand, the only GLP-1 pill that can be taken any time of day without food or water restrictions. Lowest dose starts at $199.99 for the first month and $299.99 per month ongoing; higher doses run higher.
Wegovy® Tablets - FDA-approved oral semaglutide; Wegovy is Maximus's primary on-label semaglutide product line for new patients. Lowest-dose pricing starts at $249.99 for the first month and $349.99 per month ongoing.
Zepbound® (tirzepatide injection) - FDA-approved, including for moderate-to-severe obstructive sleep apnea in adults with obesity, per the brand; Zepbound is Maximus's primary on-label tirzepatide product line for new patients. Lowest-dose pricing starts at $449.99 for the first month and $549.99 per month ongoing.
Wegovy® Pens - FDA-approved semaglutide injection. Lowest-dose pricing starts at $349.99 for the first month and $449.99 per month ongoing.
Ozempic® - FDA-approved semaglutide injection, but per the brand's own help center, Maximus prescribes Ozempic off-label for weight management; Wegovy is the on-label semaglutide option for chronic weight management, and Ozempic's own FDA approval covers type 2 diabetes. Lowest-dose pricing starts at $349.99 for the first month and $449.99 per month ongoing.
Mounjaro® - FDA-approved tirzepatide injection, but per the brand's help center, Maximus prescribes Mounjaro off-label for weight management; Mounjaro's own FDA approval covers type 2 diabetes, while Zepbound is the on-label tirzepatide option for chronic weight management. All doses start at $1,249.99 for the first month and $1,349.99 per month ongoing, per the brand - by far the highest price point Maximus displays for any GLP-1 option.
According to the brand, all compounded GLP-1 formulations use only the base form of semaglutide and tirzepatide - not salt forms such as "semaglutide sodium" or "semaglutide acetate," which the brand describes as chemically different and untested for safety or effectiveness. The brand's compounded GLP-1 formulations also include glycine and vitamin B12 as additives, which the brand states are intended to support muscle retention and energy metabolism during weight loss; this specific combined formulation has not itself been evaluated by the FDA (more on that below).
Buyer takeaway: the price gap between the cheapest compounded option and Mounjaro's roughly $1,350 ongoing monthly rate is enormous. That spread - not any single feature difference - is the biggest lever in this decision.
Buyer takeaway: the compounded-versus-brand-name choice isn't just about price. It's a genuine regulatory-status difference, and the right answer depends on whether you specifically want an FDA-approved finished product or are comfortable with a compounded formulation prepared under a physician's individual prescription.
See which Maximus GLP-1 option fits your budget
Microdose Options: The Budget Tier Most Coverage Skips
Most reviews of Maximus focus on the standard-dose tirzepatide and semaglutide plans above and stop there. Maximus also sells microdose versions of both - a genuinely separate product line, not just a lower dial on the same prescription.
Per the brand's own product pages, Semaglutide Microdose and Tirzepatide Microdose are structured as a 10-week protocol with a predetermined dose that "cannot be adjusted," according to the brand - different from the standard protocol's flexible monthly dose titration. The brand markets these starting around $79.99/month for semaglutide microdose and $99.99/month for tirzepatide microdose, positioned for people with tolerability concerns or anyone who wants to start lower and slower than the standard protocol.
This article could not independently confirm an exact ongoing per-month rate for microdose plans beyond the brand's own homepage teaser figures - unlike the standard-dose pricing above, which is cross-checked against the help center's detailed first-month/ongoing table, the microdose pages reviewed for this article didn't display that same level of detail. Confirm your specific microdose pricing, structure, and commitment length before you enroll.
Buyer takeaway: microdose is the cheapest way into a Maximus GLP-1 prescription, but it's a different structure, not just a smaller dose of the standard plan - and it comes with its own, separately confusing state-availability question (see Verify #4 below).
See if Maximus microdose is your lower-cost option
The FDA Warning Letter Maximus Still Hasn't Fully Fixed
This is the detail most other Maximus coverage won't have, and it's the reason this article's title says "still haven't fixed": the FDA actually sent Maximus Health, Inc. a warning letter, and - as detailed below - some of the exact language it flagged is still live on Maximus's own homepage today. It's real, it's public, and it's specifically about the compounded semaglutide and tirzepatide claims this article is evaluating.
The letter - reference number MARCS-CMS 730095, dated June 8, 2026, from the FDA's Center for Drug Evaluation and Research (CDER), addressed to Maximus Health, Inc. at its Santa Monica, CA address - followed an FDA review of maximustribe.com conducted in May 2026. The FDA cited two specific problems, both under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act:
Marketing language the FDA found on the site - phrases like "clinically studied ingredients," "clinically studied to help patients," and "proven to lose weight effectively" - represented compounded drug products as FDA-approved or independently evaluated for safety and effectiveness, when they weren't.
The site described its compounded-medication sources as "FDA approved pharmacies." Per the FDA, no such designation exists - compounding pharmacies and outsourcing facilities are never "FDA-approved" or "FDA-licensed," so describing one that way is false and misleading on its own.
The FDA gave Maximus 15 business days to respond in writing, identifying who produces its compounded products, providing sample labeling, and addressing or removing the flagged claims. As of this review, at least two of the exact flagged phrases are still visible on Maximus's own homepage: "Proven to lose weight effectively" appears on the Tirzepatide product card, and "Clinically studied ingredients. Real results." appears as a section headline. This article did not check every page on the site, so it can't confirm the full scope of what has or hasn't changed since the letter - but the specific language the FDA called out by name has not been fully removed from the pages checked for this review. Verify the current live claims yourself, and don't treat any "clinically studied" or "FDA approved pharmacy" language on any compounded-medication site at face value.
Read the full letter directly: FDA.gov warning letter MARCS-CMS 730095.
Buyer takeaway: a warning letter isn't a product recall or a finding that the medication itself is dangerous - it's the FDA saying specific marketing language was false or misleading. That distinction matters, but so does the letter itself: it's real, it's dated, and it's worth reading in full before you decide how much weight to give any of Maximus's other marketing claims.
Separately from that letter, here's what "compounded" means as a general regulatory matter. A licensed compounder may prepare a non-FDA-approved drug under applicable federal and state requirements and a valid prescription. The FDA does not review that compounded finished product for safety, effectiveness, or quality before it's dispensed - a meaningfully different regulatory path than a brand-name product like Ozempic or Zepbound has completed. There is no FDA-approved generic version of Ozempic, Wegovy, Mounjaro, or Zepbound as of this review. Beyond the Maximus-specific letter above, the FDA has separately warned telehealth marketers more broadly, across multiple rounds of warning letters in 2025 and 2026, against describing compounded semaglutide or tirzepatide as a "generic version" of an approved drug or as containing the "same active ingredient" in a way that implies equivalent safety or effectiveness. The FDA has warned that this kind of claim may be false or misleading, since the agency hasn't evaluated the compounded product itself.
The FDA has generally recommended that patients and providers rely on an FDA-approved product when one is commercially available, rather than a compounded version. The agency has also raised specific concerns about compounded semaglutide and tirzepatide products more broadly, including dosing-error reports and the use of salt forms it says lack a clear lawful basis for compounding - concerns Maximus's own base-form-only positioning appears intended to address, according to the brand's public statements.
On the product page's side-effects panel, Maximus discloses a standard GLP-1 boxed-warning-class contraindication: the medication class is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), based on rodent thyroid C-cell tumor data. The same panel lists rare but serious risks including acute pancreatitis, acute gallbladder disease, acute kidney injury, severe gastrointestinal disease, hypoglycemia, hypersensitivity reactions including anaphylaxis, aspiration risk during anesthesia, and monitoring for suicidal behavior and ideation.
Buyer takeaway: compounded status doesn't by itself determine whether a particular prescription is appropriate for you, but it carries real regulatory and quality distinctions from an FDA-approved finished product - distinctions worth reviewing with your prescriber and pharmacy before you decide, especially in light of the letter above.
Compare your compounded vs. FDA-approved options
How Enrollment Works: From Sign-Up to Medication
Understanding the actual sequence helps set realistic expectations for timeline. Per the brand's own three-step breakdown on the weight-loss product page:
Complete your evaluation. The brand states this is an online health questionnaire that takes about five minutes, with no appointment needed and no waiting room.
Physician review. According to the brand, a board-certified physician affiliated with the Maximus Medical Group Practices reviews your information and determines whether tirzepatide or semaglutide is appropriate for you. This is the step where the actual prescribing decision happens, and it is not guaranteed to result in a prescription.
Treatment delivered. If prescribed, the brand states your medication ships directly to your door in discreet, unmarked packaging. Maximus advertises free or included shipping on the plans it displays, subject to the terms shown at checkout.
What the brand's page does not spell out in detail for the GLP-1 protocol specifically is whether lab work is required before treatment begins - this is explicitly required for the testosterone protocols (CLIA-certified blood testing), but the weight-loss product page does not state whether bloodwork is a prerequisite for GLP-1 approval. Ask directly during your evaluation whether labs are required for your specific case.
Buyer takeaway: the fastest part of this process is the intake questionnaire. The part worth budgeting real time for is confirming your state eligibility, your exact price, and whether any lab work is required - none of which the five-minute intake form will necessarily surface for you upfront.
Homepage "Starting At" Prices vs. Help-Center First-Month Pricing
This is easy to overlook when comparing the different prices Maximus shows in different places, and it's worth walking through because it comes from two of the brand's own official pages, not from any outside source.
The main weight-loss product page displays "starting at" prices per 28-day supply: $198 for compounded tirzepatide and $116 for compounded semaglutide. The brand's separate help center - in an article on weight-loss plan pricing - describes a different structure entirely: compounded semaglutide starting at $149.99 for the first month and $249.99 per month ongoing, and compounded tirzepatide starting at $259.99 for the first month and $359.99 per month ongoing, with lower per-month rates available on 4, 6, and 12-month prepay plans. Neither figure is necessarily wrong - they may reflect different dose tiers, prepay terms, or promotional pricing that update independently on different parts of the site. But the homepage teaser price and the help-center breakdown don't reconcile with each other as displayed, and first-month, ongoing, dose-tier, and prepaid-plan prices shouldn't be compared as if they represent the same billing period.
The same first-month-versus-ongoing distinction applies to every FDA-approved brand-name option: the $199.99-$1,249.99 figures often cited as "starting" prices are first-month rates that include a $100 introductory discount; the standard ongoing monthly rate for each product is higher, as detailed in the product breakdown above.
There's a third pricing display, too. Maximus's homepage runs its own weight-loss teaser widget with different numbers again - tirzepatide from $132.99/month, semaglutide from $99.99/month, with microdose versions from $99.99 and $79.99 respectively. None of these three displays - homepage widget, product subpage, and help-center table - match each other exactly. That's not necessarily deceptive; homepages, product pages, and help centers on most sites update on different schedules. But it means no single page on maximustribe.com is a reliable final-price source. Screenshot whatever price you're quoted during your specific checkout flow.
Buyer takeaway: get your specific dose, plan length, first-month price, and ongoing monthly price in writing (or a screenshot) during the intake process, before you enter payment details - for whichever product and track you're considering.
What the Research Says About Semaglutide and Tirzepatide
It's worth separating the general clinical research on these two GLP-1 molecules from what Maximus itself has or hasn't independently studied about its own compounded product.
The active ingredients in both tracks have been studied at the molecule level in large trials of the FDA-approved products. According to trial data referenced on the Maximus site, the SURMOUNT-1 trial (Eli Lilly; published data through 72 weeks) found a mean 20.9% body-weight reduction at the 15mg tirzepatide dose, and the STEP-1 trial (Novo Nordisk) found adults lost a mean of roughly 15% of body weight over about a year on semaglutide. The SELECT cardiovascular outcomes trial (Ryan et al., Nature Medicine, July 2024; PMID 38740993) found a 20% reduction in major adverse cardiovascular events among 17,604 adults with pre-existing cardiovascular disease and overweight or obesity, without diabetes, on semaglutide.
Two things matter here. First, these are trial results for the specific FDA-approved brand-name products studied - Novo Nordisk's and Eli Lilly's own manufactured semaglutide and tirzepatide - not data on Maximus's compounded formulation. Clinical studies of FDA-approved products can't be used to establish that a compounded formulation has the same composition, quality, safety, effectiveness, or clinical outcomes as the studied product, and the brand's own weight-loss calculator on the page labels its projection tool with "individual results vary" and "this is a study average, not a prediction of your personal result." Second, the added glycine and B12 in the compounded formulation weren't part of what those trials studied - the FDA has said the safety and effectiveness of compounded drugs that combine semaglutide or tirzepatide with additional ingredients haven't been established through its approval process, a distinction worth raising directly with your prescribing clinician.
Buyer takeaway: large trials have evaluated the FDA-approved semaglutide and tirzepatide products specifically. Those results don't establish the effectiveness of Maximus's compounded formulation, or of any formulation containing additional ingredients - that's a question for your own results and your clinician's monitoring, not for this article to answer on the brand's behalf.
Side Effects and the Boxed Warning You Should Know About
Per the brand's own disclosure on the product page, side effects and risks break down like this:
Common side effects may include:
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Indigestion
Injection-site reactions
Fatigue
Belching
Hair loss
Heartburn
Rare but serious risks disclosed by the brand include:
Acute pancreatitis (including fatal, hemorrhagic, or necrotizing presentations)
Acute gallbladder disease
Acute kidney injury, typically secondary to dehydration
Severe gastrointestinal disease or delayed gastric emptying
Hypoglycemia, especially in combination with insulin or sulfonylureas
Hypersensitivity reactions, including anaphylaxis and angioedema
Pulmonary aspiration risk during anesthesia or deep sedation
Monitoring for suicidal behavior and ideation
Diabetic retinopathy complications in people with type 2 diabetes and pre-existing retinopathy
The thyroid C-cell tumor boxed-warning class effect described above
Contact your provider immediately if you notice:
Severe abdominal pain that doesn't go away
A lump or swelling in the neck, hoarseness, or trouble swallowing
Severe vomiting or diarrhea with signs of dehydration
Symptoms of low blood sugar
Signs of a serious allergic reaction
This safety information reflects what Maximus itself discloses on its public product page; it is not exhaustive, and it does not replace the full prescribing information your provider and pharmacy will give you if you're prescribed a GLP-1 medication.
Buyer takeaway: read the boxed-warning contraindication carefully if you or a close family member has any personal history of thyroid cancer. This is the one disclosure on the page worth flagging to your evaluating physician in your own words, not just checking a box on the intake form.
Start your Maximus health evaluation
Is the Maximus GLP-1 Program Right for You?
Run through both lists honestly. If the first one sounds like you and the second one doesn't, that's a real signal - not a sales pitch, just an honest match check.
It may be a reasonable fit if you:
Want a GLP-1 program without insurance pre-authorization hassles
Are comfortable paying out of pocket (with HSA/FSA eligibility, per the brand)
Want the option to combine weight-loss treatment with other Maximus protocols like testosterone or blood-flow support under one clinical team
Are comfortable with either a compounded formulation or willing to pay significantly more for an FDA-approved brand-name option
It may not be the right fit if you:
Specifically require insurance billing for your prescription
Want only FDA-approved brand-name medication and aren't interested in the compounded track at all
Need in-person physician visits rather than fully remote care
Aren't comfortable with self-administered weekly injections (Foundayo and Wegovy tablets sidestep this specific concern)
Buyer takeaway: the honest version of "who is this for" is someone who has already decided they want a GLP-1 medication and is choosing a delivery mechanism (direct-pay telehealth) over other paths (insurance-covered primary care, a local weight-management clinic, or a different telehealth competitor) - not someone who is undecided about whether GLP-1 treatment is appropriate for them at all. That determination is the licensed medical group's call, not this article's or Maximus's marketing.
Maximus GLP-1 Refund, Cancellation, and Return Policy Explained
Maximus doesn't publish a named, defined "guarantee" for its GLP-1 protocol the way it does for testosterone treatment (which carries a specific 10%-increase guarantee under its own terms). For GLP-1, what's published is a refund, cancellation, and return policy - worth reading closely, since "guarantee" isn't the right word for what's actually on offer here. One clarification worth making explicitly: some third-party coverage of Maximus references a "90-day money-back guarantee." Per the brand's own materials reviewed for this article, "90-day" appears to describe a starter-pack plan length (a fixed-dose, 90-day commitment) rather than a refund guarantee - this article did not find a 90-day money-back policy on any official Maximus page. Confirm directly with Maximus if a specific refund window matters to your decision.
Per the brand's Return, Refund & Subscription Policy (effective April 15, 2026, applying to U.S. orders), prescription medications carry a zero-day return window once dispensed and shipped. Maximus attributes this to federal and state restrictions on returning or redistributing dispensed medication - a reason grounded in real pharmacy regulation, though this article can't confirm how every telehealth prescriber in every state handles the same requirement.
If your order arrives damaged, defective, incorrect, or otherwise unusable, the brand states you have 14 days from delivery to contact support; Maximus states it will ship a free replacement, cover return shipping using a prepaid label, and charge no restocking fee.
Subscriptions run either month-to-month or as committed multi-month plans (3, 6, or 12 months). Per the policy, committed plans are non-refundable and cannot be ended early for a partial refund - you continue receiving shipments through the end of the committed term. Auto-renewal can be turned off at any time through the online dashboard or by email, with no phone call required, and material pricing or policy changes are disclosed by email at least 30 days before they take effect.
Separately, on the weight-loss product page's own FAQ, Maximus states that if you aren't approved for treatment following your evaluation, "you'll receive a full refund (minus the cost of the doctor consultation)." This non-approval refund isn't repeated on the dedicated refund-policy page, so if approval is a concern for you, it's worth getting written confirmation of this specific term during intake rather than relying on the FAQ language alone.
Maximus also states it may, at its sole discretion, offer credits, replacements, or refunds in exceptional circumstances beyond the written policy - these are granted case-by-case and don't guarantee future exceptions.
Buyer takeaway: the zero-day return window on dispensed medication is a pharmacy-regulation constraint Maximus attributes to federal and state law, not a Maximus-specific policy choice. The committed-plan non-refundability is the term most worth reading twice before you pick a 12-month plan over month-to-month.
Maximus GLP-1 Reviews: What Buyers Are Saying
The Maximus product page displays a small set of customer quotes labeled "Verified buyer," alongside the brand's own disclosure that these were "collected by Maximus from verified customers. Results vary." These are individual, self-reported experiences, not typical or guaranteed outcomes: one reviewer describes going from researching treatment to a doctor who "spends the time with me." Another describes a month on tirzepatide as effective, reporting being down two pant sizes with more energy. A third reports improved energy and a lower blood pressure reading alongside starting tirzepatide - an individual, self-reported account, not a measured or verified clinical outcome, and not typical for every patient.
These are brand-collected, brand-published testimonials, not independently audited third-party reviews, and the brand itself discloses that results vary between individuals. The company's official information page also states a Trustpilot rating of 4.3-plus stars across 800-plus verified reviews and separately claims more than 50,000 clients - brand-reported figures; platform, count, and date of last update were not independently confirmed for this article. Verify the current Trustpilot rating and review count directly on Trustpilot before treating it as current.
Buyer takeaway: brand-collected testimonials and brand-reported ratings are a starting point, not independent proof. Weigh them alongside your own research on Trustpilot or other third-party platforms, evaluated critically.
See current Maximus plans for yourself
BBB Rating and Complaints: What's Actually on File
This is the kind of detail that's easy to get wrong by copying an older figure from another site, so here's what's currently on the Better Business Bureau's own page for Maximus Tribe, checked directly rather than taken from a secondhand summary: a B- rating, based on 17 complaints filed against the business and the length of time the business has taken to respond to complaints. Maximus Tribe is not a BBB-accredited business. The BBB's file on Maximus Tribe was opened July 7, 2025; the business itself started February 16, 2021.
Recent complaint summaries and reviews on the BBB page describe billing and subscription issues, delayed prescription fulfillment, difficulty reaching customer support, and in at least one case a reported lapse in hormone-therapy medication supply. Some reviewers describe the experience in strong terms; others report resolved issues after persistent follow-up. BBB itself cautions that the nature of complaints and how a company responds to them matters more than the raw count, and that profiles generally cover a three-year reporting period.
Buyer takeaway: a B- with 17 filed complaints isn't a red flag by itself for a fast-scaling telehealth company processing thousands of orders, but it's not nothing either. Read a few of the actual complaint summaries on BBB's site yourself, and if you enroll, keep your own written record of every support interaction - several complaints specifically cite difficulty getting a timely response.
Things to Verify Before You Enroll
Every genuinely unconfirmed item below is something the accessible Maximus pages didn't fully answer at the time of this review - not evidence of a problem, just homework worth doing before you pay.
Verify #1 - Which specific pharmacy fills your prescription. Maximus's help center names The Pharmacy Hub as the dispensing pharmacy for name-brand plans, and EVR, FCC, or VIOS - depending on your state - for compounded plans. Ask during intake which one will fill your specific order and confirm its licensure in your state.
Verify #2 - Your exact first-month and ongoing monthly price before checkout. As detailed above, the homepage's "starting at" prices and the help center's first-month/ongoing pricing tables don't reconcile cleanly with each other. Get a specific dollar figure - both the first-month rate and the ongoing rate - in writing for your chosen dose and plan length.
Verify #3 - What support channels are actually available to you. The current Maximus Contact page lists two email addresses - support@maximustribe.com and hello@maximustribe.com - plus a live chat widget. The brand's help center describes an AI chat assistant ("Max") that hands off to a human agent on request; the materials reviewed didn't show a published phone or text-message support line. Confirm directly with Maximus which channels are available if a specific communication method matters to you.
Verify #4 - State availability for your specific protocol. Per the brand's current weight-loss FAQ, the standard protocol is available nationwide except Alabama, Mississippi, and Louisiana as of this review. But the brand's own microdose product pages state availability differently - "nationwide in all 50 states and Washington, DC," with no state exclusions listed at all. Those two statements don't match, and this article can't resolve which one is current. Confirm your specific state for your specific product (standard dose vs. microdose) during the intake questionnaire rather than relying on any single published list, including this one.
Verify #5 - Whether the non-approval refund applies to your specific plan. The full-refund-minus-consultation-fee language for non-approved applicants appears on the weight-loss FAQ but is not repeated on the dedicated Return, Refund & Subscription Policy page. Get this in writing if it factors into your decision to enroll.
Verify #6 - Whether your HSA/FSA plan actually covers this expense. Maximus accepts HSA and FSA cards at checkout, but plan eligibility for compounded prescription medications through a telehealth platform varies by administrator. Confirm with your specific plan before relying on this as your payment method.
Verify #7 - Whether the compounded formulation's added ingredients matter to you clinically. The glycine and B12 additives in the compounded GLP-1 formulations have not been evaluated in combination with semaglutide or tirzepatide through the FDA approval process. If you'd prefer a formulation studied exactly as approved, discuss the FDA-approved brand-name track with your prescribing clinician instead.
Buyer takeaway: none of these seven items are dealbreakers by themselves. Together, they're a reasonable ten-minute homework list - the kind any telehealth prescriber, not just Maximus, should be able to answer clearly before you commit a card number.
Check current Maximus pricing before you enroll
Fast Facts
FDA warning letter: MARCS-CMS 730095, issued June 8, 2026, citing false/misleading compounded-drug marketing claims - full letter on FDA.gov
BBB rating: B-, 17 complaints filed, not BBB-accredited, per BBB.org (Maximus Tribe profile)
Platform legal entity: Maximus Health, Inc.
Licensed medical group: Maximus Medical Group Practices ("Group"), per the brand's Telehealth Informed Consent
Dispensing pharmacy (name-brand plans): The Pharmacy Hub (TPH), per the brand's help center
Dispensing pharmacy (compounded plans): EVR, FCC, or VIOS, depending on the patient's state, per the brand's help center
Compounded semaglutide pricing: $149.99 first month, $249.99/month ongoing, per the brand's help center (July 2026)
Compounded tirzepatide pricing: $259.99 first month, $359.99/month ongoing, per the brand's help center (July 2026)
Foundayo™ Tablets (lowest dose): $199.99 first month, $299.99/month ongoing
Wegovy® Tablets (lowest dose): $249.99 first month, $349.99/month ongoing
Zepbound® (lowest dose): $449.99 first month, $549.99/month ongoing
Ozempic® / Wegovy® Pens (lowest dose): $349.99 first month, $449.99/month ongoing each
Mounjaro® (all doses): $1,249.99 first month, $1,349.99/month ongoing
On-label vs. off-label: Wegovy and Zepbound are Maximus's on-label options for weight management; Ozempic and Mounjaro are prescribed off-label for weight management, per the brand
Installment payment option: Klarna offered at checkout on at least one product page, per the brand - confirm availability for your specific plan
Microdose pricing: semaglutide microdose from ~$79.99/month, tirzepatide microdose from ~$99.99/month, per the brand's homepage - a separate 10-week structure, not simply a lower dose of the standard plan
Insurance: not accepted; direct-pay; HSA/FSA accepted per the brand
Return window on dispensed medication: zero days, per pharmacy regulation the brand cites
Damaged/defective claim window: 14 days from delivery
Auto-renewal cancellation: self-service via dashboard or email, no phone required
State availability (as of this review): nationwide except AL, MS, LA per the current FAQ
Certification badge displayed: LegitScript-approved seal; confirm current status and date directly on LegitScript's linked verification page
Headquarters: Los Angeles, CA per the brand's official-information page (a separate Santa Monica, CA address appears in the Terms of Use as the correspondence address)
Quick Answer: What public business and compliance information does Maximus provide?
Maximus Health, Inc. publishes a Terms of Use, a Return, Refund & Subscription Policy, a disclosed three-entity clinical structure, and a LegitScript-approved seal linked to LegitScript's own verification page. This article did not independently audit every provider's license, every pharmacy relationship, or every marketing claim - verify specifics directly before enrolling.
Quick Answer: Is compounded semaglutide the same as Ozempic?
No. Compounded semaglutide is a non-FDA-approved formulation prepared by a compounding pharmacy; it is not a generic version of Ozempic or Wegovy, and clinical trial results for the FDA-approved products don't establish the safety, effectiveness, or quality of the compounded version. There is currently no FDA-approved generic version of Ozempic or Wegovy.
Quick Answer: Does Maximus GLP-1 take insurance?
No. Per the brand, Maximus is a direct-pay platform that does not bill insurance for any protocol, including GLP-1 weight loss. HSA and FSA cards are accepted at checkout, though eligibility for compounded prescription medications varies by individual plan administrator.
Quick Answer: Can I return GLP-1 medication if I change my mind?
No. Per the brand's Return, Refund & Subscription Policy, dispensed prescription medications carry a zero-day return window because federal and state pharmacy regulations prohibit returning or reselling dispensed drugs. Damaged, defective, or incorrect orders can be reported within 14 days for a free replacement.
Get your personalized Maximus GLP-1 plan
Frequently Asked Questions
Did the FDA send Maximus a warning letter?
Yes. The FDA's Center for Drug Evaluation and Research sent Maximus Health, Inc. a warning letter (reference number MARCS-CMS 730095) on June 8, 2026, following a review of maximustribe.com conducted in May 2026. The letter cited two issues: marketing phrases like "clinically studied ingredients" and "proven to lose weight effectively" that the FDA said falsely implied its compounded products were FDA-evaluated, and language describing its pharmacy sources as "FDA approved," a designation the FDA says doesn't exist for compounding pharmacies. Maximus had 15 business days to respond. As of this review, both of those exact phrases are still visible on the Maximus homepage - read the full letter on FDA.gov and check current site language yourself before assuming anything has changed.
What is Maximus's BBB rating?
Per BBB.org, Maximus Tribe currently holds a B- rating, based on 17 complaints filed against the business and the length of time it has taken to respond to some of them. Maximus Tribe is not a BBB-accredited business. Complaint summaries on the BBB page describe billing disputes, delayed prescription fulfillment, and difficulty reaching support; some reviewers report issues were eventually resolved. BBB notes that how a company responds to complaints matters as much as the raw count - read a few of the actual filed complaints yourself before weighing this against the rest of your research.
Is Maximus GLP-1 legit or a scam?
Maximus is an operating, registered telehealth company - it's not a fake storefront or a lottery-style scheme. That said, "legit company" and "scam-free experience" are different questions. Maximus has a real FDA warning letter on file over marketing-claim accuracy, a B- BBB rating with 17 complaints, and marketing pages with pricing figures that don't always reconcile with each other. None of that makes it a scam in the legal sense, but it does mean the burden is on you to verify pricing, refund terms, and support responsiveness yourself rather than taking any single page's claims at face value.
Is Maximus a legally registered company?
Maximus Health, Inc. is a registered telehealth company with a published Terms of Use, a Return, Refund & Subscription Policy, and a disclosed three-entity clinical structure separating the platform, the licensed medical group, and the compounding pharmacy. The site displays a LegitScript-approved seal linking to LegitScript's own verification page, and the brand states it has raised venture funding from firms including Founders Fund and 8VC. None of this substitutes for verifying the specific terms, pricing, guarantee conditions, and state availability that apply to your own situation before you enroll and submit payment information.
Who actually prescribes the medication - Maximus or a doctor?
Neither Maximus Health, Inc. directly. Per the brand's own Terms of Use, Maximus does not provide medical advice, medical services, or medical care and does not itself prescribe. Prescribing decisions are made independently by licensed physicians affiliated with the Maximus Medical Group Practices - referred to in the brand's own consent documents as "Group" - based on your intake information and, where required, lab work. Maximus states that it performs only administrative, payment, and supportive activities on behalf of Group and its providers. A prescription is never guaranteed, and the evaluating physician can decline to prescribe, recommend a different protocol, or request additional information before making a clinical decision.
Does Maximus offer a microdose GLP-1 option?
Yes. Per the brand's own product pages, Maximus sells Semaglutide Microdose and Tirzepatide Microdose as a separate 10-week protocol with a predetermined dose, marketed starting around $79.99/month and $99.99/month respectively. This isn't simply a smaller dose of the standard plan - it's a distinct structure with its own commitment length. This article could not independently confirm an exact ongoing per-month rate for microdose the way it could for the standard-dose plans, so get that figure in writing before you enroll.
What's the difference between the compounded and FDA-approved GLP-1 options?
Compounded tirzepatide and semaglutide are prepared by a licensed compounding pharmacy based on an individual prescription and are not FDA-approved finished products. FDA-approved options - Ozempic, Wegovy, Zepbound, Mounjaro, and Foundayo - are manufactured brand-name products that have completed FDA review. Clinical trial results for the FDA-approved products can't be used to establish that the compounded version shares the same composition, quality, safety, or effectiveness. The FDA-approved track costs substantially more on the Maximus site; whether it's more likely to qualify for insurance coverage elsewhere depends on your specific plan, since Maximus itself doesn't bill insurance for either track.
How much does Maximus GLP-1 actually cost?
Per the brand's help center, compounded semaglutide starts at $149.99 for the first month and $249.99 per month ongoing; compounded tirzepatide starts at $259.99 for the first month and $359.99 per month ongoing, with lower per-month rates on prepay plans. FDA-approved options range from $199.99 first month (Foundayo, lowest dose) up to $1,249.99 first month (Mounjaro, all doses), with ongoing rates roughly $100 higher than the first-month rate on most products. The main product page separately displays "starting at" teaser prices that don't cleanly reconcile with the help-center breakdown - confirm your specific first-month and ongoing cost during intake.
Does Maximus require insurance?
No. Maximus operates as a direct-pay telehealth platform and does not bill insurance for GLP-1 treatment, whether you choose the compounded or FDA-approved track. According to the brand, the pricing shown at checkout is meant to be transparent and cover the doctor consultation, the medication if prescribed, and ongoing clinical support in a single protocol cost. HSA and FSA cards are accepted as payment methods, though individual plan eligibility for compounded prescription medications through a telehealth platform varies by administrator - confirm coverage with your specific plan before relying on this payment method for a multi-month commitment.
What happens if I'm not approved for treatment?
According to the weight-loss product page's own FAQ, applicants who aren't approved for treatment receive a full refund minus the cost of the doctor consultation. That means the consultation fee itself is treated as earned and non-refundable even when no prescription results, while the remainder of what you paid is returned. This specific term is not repeated on the brand's dedicated Return, Refund & Subscription Policy page, which focuses on dispensed-medication and subscription terms instead, so it's worth getting written confirmation of this exact non-approval refund language during your intake process, before you submit payment, rather than relying on the FAQ page alone.
Can I cancel my Maximus GLP-1 subscription at any time?
It depends on your plan type. Month-to-month plans can be turned off at any time through the online dashboard or by email, with no phone call required, and the plan simply ends at the close of the current month. Committed multi-month plans (3, 6, or 12 months), however, cannot be ended early for a partial refund - you continue to receive shipments through the end of the committed term regardless of when you request cancellation.
Can I return GLP-1 medication that has already shipped?
No. Per the brand's Return, Refund & Subscription Policy, dispensed prescription medications have a zero-day return window because federal and state pharmacy regulations prohibit returning or reselling dispensed drugs, regardless of whether the medication has been opened, used, or is still sealed. This applies equally to compounded and FDA-approved orders shipped through Maximus. Damaged, defective, or incorrect shipments are handled as a separate category: report the issue within 14 days of delivery, and Maximus states it will ship a free replacement, cover return shipping with a prepaid label, and charge no restocking fee.
See today's Maximus GLP-1 plans
What side effects does Maximus disclose for its GLP-1 medications?
Per the brand's own product page, common side effects may include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, belching, and hair loss. Rare but serious risks disclosed include acute pancreatitis, acute gallbladder disease, acute kidney injury, severe gastrointestinal disease, hypoglycemia, hypersensitivity reactions including anaphylaxis, aspiration risk during anesthesia, and a boxed-warning-class contraindication for people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, based on rodent thyroid C-cell tumor data for this medication class as a whole, not specific to Maximus's formulation.
Is compounded tirzepatide as effective as Mounjaro or Zepbound?
Trials like SURMOUNT-1 studied the FDA-approved tirzepatide products manufactured by Eli Lilly, finding a mean 20.9% body-weight reduction at the highest studied 15mg dose over 72 weeks, according to data the brand itself cites. That trial data doesn't establish the effectiveness of Maximus's compounded formulation, which additionally includes glycine and B12 and hasn't been independently studied as a combined formulation through any published clinical trial. Individual results vary considerably, and this distinction is worth discussing directly with your prescribing clinician before you decide between tracks.
Does Maximus name the specific pharmacy that fills GLP-1 prescriptions?
Yes, for both tracks. Maximus's help center names The Pharmacy Hub (TPH) as the dispensing pharmacy for name-brand plans, and one of three licensed 503A compounding pharmacies - EVR, FCC, or VIOS - for compounded plans, depending on the patient's state. If pharmacy transparency matters to your decision, ask directly during intake which specific pharmacy will fill your prescription, and independently verify that pharmacy's state licensure and standing through your state board of pharmacy before your first shipment arrives.
Can I combine the GLP-1 protocol with other Maximus treatments?
According to the brand, yes - the weight-loss protocol is described as compatible with other Maximus protocols, including testosterone optimization, hair growth, blood flow support, and the oxytocin calming cream, as part of a broader health-optimization plan covering multiple hormonal and metabolic goals under one clinical team. The company's own materials position this multi-protocol coordination as a differentiator relative to single-category telehealth competitors. That said, the evaluating clinician - not the platform or its marketing - determines whether combining treatments is clinically appropriate for your specific health profile, current medications, and lab results.
What states is the Maximus weight-loss protocol available in?
Per the current product-page FAQ, the protocol is available nationwide except Alabama, Mississippi, and Louisiana as of this review. Because Maximus's own published availability language has changed over time - an earlier version of the brand's materials referenced different excluded states - confirm your specific state directly during the intake questionnaire rather than relying solely on any single published list, including this one, before you begin the enrollment process or make plans around a specific start date.
Is the glycine and B12 added to Maximus's compounded GLP-1 formulations approved by the FDA?
No. The FDA has not established the safety and effectiveness of compounded drugs that combine semaglutide or tirzepatide with additional ingredients like glycine and vitamin B12 through its formal approval process. This article did not identify independent clinical evidence establishing the safety or effectiveness of this specific combined formulation - that doesn't necessarily mean it's unsafe, but it does mean this exact combination hasn't gone through FDA review as a finished product the way Ozempic or Zepbound has. That's a point worth raising directly with your prescribing clinician before starting treatment, particularly if you have any sensitivity to added ingredients.
How do I contact Maximus with questions before enrolling?
Per the brand's current Contact page, published channels are support@maximustribe.com for customer support - the brand recommends using the live chat widget for the fastest turnaround - and hello@maximustribe.com for general inquiries. The brand's help center describes an AI chat assistant ("Max") that can hand off to a human support agent when needed. A phone or text-message support line was not confirmed in the pages reviewed for this article; if that matters to you, ask directly during signup or check your dashboard for current contact options.
Buyer Verification Checklist
Confirm your exact dose, plan length, and total monthly price in writing before entering payment information.
Ask which specific pharmacy fills your prescription (The Pharmacy Hub for name-brand plans; EVR, FCC, or VIOS for compounded plans, depending on your state) and verify its licensure.
Confirm whether your state is currently eligible for the weight-loss protocol during the intake questionnaire.
Get written confirmation of the non-approval refund terms if approval odds concern you.
Check with your HSA/FSA plan administrator that compounded GLP-1 medication qualifies as a reimbursable expense.
Decide upfront whether you want the compounded track or the FDA-approved brand-name track, and confirm which one your evaluating clinician recommends.
Review the full Return, Refund & Subscription Policy on the official site before choosing a month-to-month versus committed multi-month plan.
Ask your provider directly about the boxed-warning contraindications (personal or family history of MTC or MEN 2) before starting treatment.
Buyer takeaway: print or screenshot this checklist and work through it during your intake call or chat session - it takes less time than the five-minute health questionnaire itself, and it's the fastest way to convert "brand-stated" into "confirmed for my specific case."
Start your Maximus GLP-1 evaluation today
The Bottom Line
Maximus GLP-1 is a direct-pay telehealth option for people who want a compounded or FDA-approved GLP-1 prescription without navigating insurance pre-authorization. The three-entity structure - Maximus Health, Inc. as the platform, the Maximus Medical Group Practices as the prescribing physicians, and a named pharmacy fulfillment partner (The Pharmacy Hub for name-brand plans; EVR, FCC, or VIOS for compounded plans) - is disclosed clearly enough to know who's responsible for what.
The displayed compounded-plan prices are lower than the displayed cash prices for the brand-name options shown on Maximus's own site, but the homepage's "starting at" figures and the help center's first-month/ongoing pricing tables don't fully reconcile with each other, and that's worth nailing down to a specific first-month and ongoing dollar figure before you check out. The refund and cancellation terms are relatively clear for a prescription telehealth product - dispensed medication can't be returned per the pharmacy regulation the brand cites, damaged orders get a free replacement, and month-to-month plans can be canceled without a phone call - but the non-approval refund language lives only in the FAQ, not the formal policy page, so get that in writing if it matters to your decision.
None of this is a reason to avoid Maximus specifically. It's a reason to work through the verification items above, get your answers in writing, and make your decision based on your own confirmed first-month and ongoing numbers rather than whichever price loads first.
Buyer takeaway: the decision that matters most here isn't "Maximus or not" - it's compounded versus FDA-approved, on-label versus off-label product line, and month-to-month versus committed term. Get clarity on those choices first, and the rest of the enrollment steps are quick by comparison.
Maximus Contact Information
Per the brand's current Contact page, here's how to reach Maximus directly:
Customer support: support@maximustribe.com (live chat recommended for the fastest response)
General inquiries: hello@maximustribe.com
Chat support: an AI chat assistant that hands off to a human agent on request, per the brand's help center
Mailing address: 2219 Main Street, #347, Santa Monica, CA 90405 (per the brand's Terms of Use)
Phone or text: not confirmed on the pages reviewed for this article
Official site: maximustribe.com
Start your Maximus GLP-1 evaluation today
Material Limitations: This article is based on the Maximus product page, homepage, Contact page, Terms of Use, Return, Refund & Subscription Policy, and help-center pricing and pharmacy articles as published on the official site, the brand's own official-information and Telehealth Informed Consent pages, and FDA warning letter MARCS-CMS 730095 (posted on FDA.gov), at the time of research. No product was tested, and no brand claim - including pricing, refund terms, clinical positioning, or customer-satisfaction figures - has been independently verified by this publication beyond what the brand itself discloses or the FDA has published. This article confirmed that two of the specific phrases named in the FDA's letter remain visible on Maximus's homepage as of this review, but did not check every page on the site for the full scope of what has or hasn't changed. Facts that could not be confirmed on accessible pages - including a single specific legal entity name for the Maximus Medical Group Practices beyond that collective term, and a currently published phone or text support line - are named above under Things to Verify and were omitted from the claims rather than assumed. Some links in this article route through an affiliate intermediary rather than directly to the brand's own domain. Contact the brand directly to verify any material claim before enrolling.
Third-Party Feedback Platforms: The accuracy of third-party review platforms, including Trustpilot, is not endorsed by this article. Evaluate any third-party rating or review critically and verify current figures directly on the platform in question.
Forward-Looking Statements: This article reflects information reviewed in July 2026. Pricing, refund terms, state availability, and pharmacy partnerships may change without notice. Rely on the brand's official website for current information before making any purchasing decision.
Marketing Language Notice: Attribution language throughout this article identifies statements as brand claims. Title and section phrasing reflect brand-asserted marketing language and this article's own editorial framing - not independent rankings, lab-verified claims, or regulatory findings.
California buyers should verify the product label and any applicable Proposition 65 warnings published by the manufacturer or compounding pharmacy before purchase. This product involves prescription medication shipped to the buyer; no Proposition 65 warning specific to this product was identified in the materials reviewed for this article, and California buyers should confirm current disclosures directly with Maximus or the fulfilling pharmacy.
Geographic and Jurisdiction Notice: This article and the Maximus GLP-1 program are intended for U.S. residents. Availability, pricing, and regulatory requirements referenced in this article apply to the United States and may not reflect availability, terms, or legality in other jurisdictions.
Trademark Acknowledgment: Ozempic®, Wegovy®, Mounjaro®, and Zepbound® are registered trademarks of their respective manufacturers (Novo Nordisk and Eli Lilly and Company) and are used here for identification and comparison purposes only; Maximus is not affiliated with, endorsed by, or a manufacturer of these branded products. Foundayo™ is used by the brand with a trademark symbol as shown on the official site; no independent trademark registration search was performed for this article.
SOURCE: Maximus
View the original press release on ACCESS Newswire